pentoxifylline has been researched along with Arteriosclerosis, Coronary in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 9.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| " We sought to determine whether treatment with pentoxifylline, a phosphodiesterase inhibitor with immunomodulating properties, could reduce the pro-inflammatory response observed in patients with acute coronary syndromes (ACS) and increase anti-inflammatory activity." | 9.13 | Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study. ( Blotta, MHSL; Coelho, OR; de Oliveira, RTD; Fernandes, JL; Mamoni, RL; Nicolau, JC; Serrano, CV, 2008) |
| "Pentoxifylline treatment can suppress the CD40/CD40 ligand system activation in CAD patients." | 6.77 | Pentoxifylline decreases soluble CD40 ligand concentration and CD40 gene expression in coronary artery disease patients. ( Behravan, J; Falsoleiman, H; Mohammadpour, AH; Ramezani, M; Shamsara, J, 2012) |
| "As pentoxifylline could suppress the inflammatory process and has shown some promising beneficial effects in inflammatory diseases, we evaluated the effect of two months pentoxifylline administration in proteome of PBMCs of patients with coronary artery disease (CAD)." | 6.76 | Pentoxifylline administration changes protein expression profile of coronary artery disease patients. ( Behravan, J; Falsoleiman, H; Mohammadpour, AH; Ramezani, M; Rendeirs, J; Shamsara, J, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 5.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| " We sought to determine whether treatment with pentoxifylline, a phosphodiesterase inhibitor with immunomodulating properties, could reduce the pro-inflammatory response observed in patients with acute coronary syndromes (ACS) and increase anti-inflammatory activity." | 5.13 | Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study. ( Blotta, MHSL; Coelho, OR; de Oliveira, RTD; Fernandes, JL; Mamoni, RL; Nicolau, JC; Serrano, CV, 2008) |
| "Pentoxifylline treatment can suppress the CD40/CD40 ligand system activation in CAD patients." | 2.77 | Pentoxifylline decreases soluble CD40 ligand concentration and CD40 gene expression in coronary artery disease patients. ( Behravan, J; Falsoleiman, H; Mohammadpour, AH; Ramezani, M; Shamsara, J, 2012) |
| "As pentoxifylline could suppress the inflammatory process and has shown some promising beneficial effects in inflammatory diseases, we evaluated the effect of two months pentoxifylline administration in proteome of PBMCs of patients with coronary artery disease (CAD)." | 2.76 | Pentoxifylline administration changes protein expression profile of coronary artery disease patients. ( Behravan, J; Falsoleiman, H; Mohammadpour, AH; Ramezani, M; Rendeirs, J; Shamsara, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shamsara, J | 2 |
| Behravan, J | 2 |
| Falsoleiman, H | 2 |
| Mohammadpour, AH | 2 |
| Rendeirs, J | 1 |
| Ramezani, M | 2 |
| Ueno, M | 1 |
| Ferreiro, JL | 1 |
| Tomasello, SD | 1 |
| Tello-Montoliu, A | 1 |
| Capodanno, D | 1 |
| Seecheran, N | 1 |
| Kodali, M | 1 |
| Dharmashankar, K | 1 |
| Desai, B | 1 |
| Charlton, RK | 1 |
| Bass, TA | 1 |
| Angiolillo, DJ | 1 |
| Firouzi, A | 1 |
| Eshraghi, A | 1 |
| Shakerian, F | 1 |
| Sanati, HR | 1 |
| Salehi, N | 1 |
| Zahedmehr, A | 1 |
| Kiani, R | 1 |
| Madani, M | 1 |
| Pedarzadeh, A | 1 |
| Fernandes, JL | 1 |
| de Oliveira, RTD | 1 |
| Mamoni, RL | 1 |
| Coelho, OR | 1 |
| Nicolau, JC | 1 |
| Blotta, MHSL | 1 |
| Serrano, CV | 1 |
| Franz, N | 1 |
| Linss, G | 1 |
| Modersohn, D | 1 |
| Richter, K | 1 |
| Lange, T | 1 |
5 trials available for pentoxifylline and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Pentoxifylline administration changes protein expression profile of coronary artery disease patients.
Topics: Calgranulin B; Coronary Artery Disease; Electrophoresis, Gel, Two-Dimensional; Female; HSP72 Heat-Sh | 2011 |
Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabe | 2011 |
Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients.
Topics: Acute Kidney Injury; Adult; Angioplasty, Balloon, Coronary; Contrast Media; Coronary Angiography; Co | 2012 |
Pentoxifylline decreases soluble CD40 ligand concentration and CD40 gene expression in coronary artery disease patients.
Topics: CD40 Antigens; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Female; Gene Expression Re | 2012 |
Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Coronary Artery Disease; Female; Humans; Inflammation; | 2008 |
1 other study available for pentoxifylline and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
[Acute changes in global and regional systolic heart function caused by pentoxifylline in patients with and without coronary sclerosis].
Topics: Coronary Artery Disease; Female; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; My | 1988 |